Evidence from proviral tagging experiments has suggested that pim-2 is similar in oncogenic behavior to its well characterized relative pim-1. While the basal expression in tissues diers, both genes are highly expressed in mitogenically stimulated hematopoietic cells and their transcription is induced in response to the same cytokines. Expression of a pim-2 transgene in lymphoid cells predisposed mice to T-cell lymphomas like those promoted by pim-1 transgenes. Moreover, strong collaboration with an Em-myc transgene was manifested as pre-B cell leukemia in neonate bi-transgenic animals. Remarkably, this collaboration was attenuated but not prevented by X-inactivation of one of the transgenes. The addition of pim-2 to the fold increases the prominence of the pim proto-oncogene family in tumorigenesis.
Introduction
Pim-2 was identi®ed by virtue of sequence conservation with the pim-1 oncogene and implicated in lymphomagenesis by its presence as a common proviral integration site in Moloney murine leukemia virus (MuLV) induced lymphomas . Pim-1 was itself ®rst identi®ed as a common integration site of MuLV (Cuypers et al., 1984; Selten et al., 1985) and subsequently found to be overexpressed in a variety of cell lines and primary tumors (Amson et al., 1989) . Pim-1 encodes a very labile cytoplasmic protein serine-threonine kinase (Selten et al., 1986; Saris et al., 1991) and pim-2 proved to have similar biochemical properties in vitro (van der . The oncogenic consequences of pim-1 overexpression were clearly demonstrated in transgenic mice (van Lohuizen et al., 1989a) . A notable feature of pim-1's action in this respect is the potency of its collaboration with a c-myc transgene, or with proviral activation of either c-myc or N-myc (van Lohuizen et al., 1989a,b; Verbeek et al., 1991) . Pim-1 is induced and stabilized by a variety of cytokines (Dautry et al., 1988; Wingett et al., 1991; Lilly et al., 1992; Domen et al., 1993a; Buckley et al., 1995; Nagata and Tokodoro, 1995; Yip et al., 1995) and it is clear that this is not merely an incidental eect, as its inactivation by gene targeting resulted in reduced responses to IL-3 and IL-7 in vitro while, conversely, the IL-7 response was enhanced in cells from pim-1 transgenic mice (Domen et al., 1993a; Domen et al., 1993b) . However, the precise biological role of pim-1 and the identity of it's cellular substrates remain unknown.
Accumulating evidence Scheijen et al., 1997) indicates that pim-2 is activated about as frequently as pim-1 by MuLV insertion. Pim proto-oncogenes are therefore activated in a considerably larger proportion of retrovirus-induced lymphomas than previously thought. Simultaneous activation of both pim-1 and pim-2 by MuLV in a clonal tumor has never been observed, a clear indication that their functions are equivalent in this context. Indeed, in the presence of a c-myc transgene, ablation of one or both copies of pim-1 led to greatly increased frequency of activation of pim-2 by MuLV (van der , indicating functional substitution of pim-2 for pim-1. This result also implied that wild-type levels of pim-1 (and pim-2) are permissive for lymphogenesis by a myc transgene, but not optimal, and that decreasing the wild-type level of pim-1 through reduced gene dosage increased the selective advantage of cells harboring activations of pim-2 (or a remaining copy of pim-1 in heterozygotes). Increased pim-2 expression should therefore have a signi®cant eect on the rate of tumorigenesis by a myc transgene.
Evidence for functional similarities and/or differences of the two pim genes in lymphomagenesis is pertinent to interpretation of their roles in normal lymphoid cells. Functional overlap would, for example, partly explain the weak phenotypes in vivo from inactivating either pim-1 or pim-2 by gene targeting (Domen et al., 1993c; Laird et al., 1993 and J Allen unpublished data) . We have therefore sought to characterize the tumorigenic properties of pim-2 by expression of a transgene in the mouse lymphoid compartment. The data con®rm that pim-2 is an oncogene, that it collaborates potently with c-myc even when only modestly over-expressed, and that the resulting tumors are like those obtained previously with a pim-1 transgene. Thus, in the context of lymphomagenesis, the two genes have equivalent functions.
Results

Expression of endogenous and transgenic pim-2
The low level basal expression of pim-2 mRNA in mouse tissues resembles that of pim-1 but the pattern is distinct, for example in brain and testis (Figure 1a) . In hematopoietic tissues pim-2 expression is nevertheless similar to that of pim-1, being found in the lymphoid organs and bone marrow and at high levels in cells stimulated with mitogens or cytokines. Like pim-1, pim-2 mRNA is induced by a variety of cytokines having receptors of the hemopoietin class, including interleukins 2, 3, 4, 7 and 9 and g-interferon but not by cytokines with a membrane tyrosine kinase receptor, such as SCF (Figure 1b) .
Activation of pim-2 invariably occurs via overexpression of the normal protein, as for pim-1. In model systems employing Moloney MuLV as an insertional mutagen (Jonkers and Berns, 1996) , pim-2 over-expression is directed by the enhancers in the provirus and sometimes also proviral truncation of mRNA instability motifs in the 3' untranslated region of the coding sequence . The pim-2 transgene (Figure 2a ) mimics these modes of activation. The vector (courtesy of M Alkema) was itself derived from an MuLV integration in the pim-1 gene cloned from a tumor (van Lohuizen et al., 1989a) , by addition of tandem immunoglobulin m heavy chain enhancers. The combination gives reliable transgene expression in lymphoid cells of both the B and T cell lineages (van Lohuizen et al., 1989a; Renauld et al., 1994; Alkema et al., 1995) .
Two transgenic lines were generated, pim-2 18 and pim-2 30, both of which have single copy integrations.
Additional founders with higher transgene copy number were obtained but died before reproducing, in at least two cases, of lymphoma. The inheritance pattern of the transgene in line 18 revealed that it was X-linked. Males were therefore used in the analysis of transgene expression. Both transgenic lines showed increased pim-2 mRNA expression in their lymphoid tissues. Line 30 expressed several times the level of pim-2 mRNA in spleen and thymus as non-transgenic litter mates (Figure 2b ) while total pim-2 expression in line 18 was lower, about twice the normal level.
Lymphomagenesis in pim-2 transgenic line 30
Mice from the higher-expressing transgenic line 30 developed T-cell lymphomas, with the incidence reaching 40% by 1 year of age (Figure 3 ). Tumor incidence showed no bias according to the gender of the mice or their transgenic parents ± there was no evidence of marked imprinting eects. In most cases the principal tumor site was the thymus, and of eight tumors examined by¯ow cytometry, all were CD4 ± no TCRgd + tumors were observed. The tumors were clonal as judged by TCRb chain gene rearrangements ( Figure 5 ). Histological analysis of tissue sections indicated little tendency to spread beyond the lymphoid organs or indeed, the thymus itself. Sections showed loss of cortical-medullary substructure in the thymus, frequent mitoses and pinocytic or necrotic cells (Figure 6a ). In these characteristics the tumors were similar to those seen in pim-1 transgenic mice and described previously (van Lohuizen et al., 1989a) .
Only one tumor was observed in the pim-2 transgenic line 18 cohort ( Figure 3 ) and no others have been observed since, so the spontaneous tumor incidence is essentially indistinguishable from background. Transgene expression can normally be increased by generating homozygotes, but X-linkage of the transgene thwarts this stratagem: the copy on the inactive chromosome should be silent. Expression of the pim-2 transgene in this line is nevertheless sucient to display potent synergy with a collaborating oncogene, as described below.
There was no evidence of a marked preneoplastic phenotype in either of the pim-2 transgenic lines. Healthy mice appeared normal upon histological examination. Hematopoietic cell populations from the bone marrow, spleen, thymus and peritoneal cavity of mice from the transgenic lines were checked at ages from 3 weeks to 12 weeks and comparison with nontransgenic litter mates showed no signi®cant dierences in either total cell counts or in the relative sizes of the major lymphoid and myeloid lineage subsets, as determined by¯ow cytometry (e.g. Figure 4a ). The absence of a marked pre-neoplastic phenotype in vivo suggests either that the target cell population is small, or that additional oncogenic events are required to aect it's normal growth. A good candidate in this respect is activation of a myc gene since, as is almost invariably observed in lymphoid tumors, the pim-2 30 tumors all expressed signi®cant levels of c-myc and/or N-myc (not shown).
Collaboration of pim-2 with c-myc
Given the striking synergy between pim-1 and c-myc in tumorigenesis, it was important to establish whether pim-2 behaves similarly. To this end, the pim-2 transgenic lines were crossed with Em-myc transgenic mice. The Em-myc line 186 and similar lines have been described elsewhere (Adams et al., 1985; Verbeek et al., 1991; Materials and methods) . Most of the mice succumb to spontaneous pre-B or B cell lymphomas by 1 year of age, although a small proportion of the 186 line develops T-cell lymphomas. It is noteworthy that the myc transgene in this line is also X-linked.
Bi-transgenic progeny of the Em-myc and the (higher-expressing) pim-2 line 30 were all aicted with severe leukemia and died between 3 and 4 weeks of age if not sacri®ced earlier. They were normal in appearance at birth but noticeably retarded in growth thereafter. At normal weaning age (20 days), the bitransgenics averaged less than half the weight of their litter mates (5 g vs 13 g). A consistent leukemic phenotype was observed in each of six cases examined at this stage, illustrated by peripheral blood smears (Figure 6b ). White blood cell counts ranged from 1 to 5610 8 per ml and all the mice were severely anaemic. The tumors consisted of large undierentiated lymphoblastoid cells in®ltrating most tissues (e.g. Figure 6c ). Figure 5 . The k light chain, however, remained in the germline con®guration in all the tumors. Histological examination of 2 day old bi-transgenics showed that the leukemias were already well advanced by this age (Figure 6d ). Two of four such tumors from newborns were transplantable to syngeneic hosts, while all four gave rise to IL-7 and/or SCF dependent cell lines in vitro (Materials and methods).
Some, though not all, bi-transgenic mice harboured simultaneous T-cell lymphomas. These were manifested in signi®cant numbers of large CD4 + 8 + T cells in the periphery. In two such cases where the thymus was checked by¯ow cytometry, thymic lymphomas were present (not shown). The T cell tumors were also evident as dominant rearrangements of the TCRb locus in DNAs derived from the thymus and sometimes, less prominently, peripheral lymphoid organs ( Figure 5 ). They thus appear to have been of clonal origin.
Crossing the pim-2 18 and Em-myc lines was less straightforward as both transgenes are X-linked. Xinactivation silences one of the transgenes in each cell of the bi-transgenic F1 females, in principle preventing collaboration (no bi-transgenic male F1s are produced). Mating these females with non-transgenic males produced some progeny that were also bitransgenic (6 out of 36) via meiotic recombination between the X chromosomes. As the two transgenes must then reside on the same X chromosome, they should thus be active together in the same cells.
Despite the lower transgene expression and insignificant rate of spontaneous lymphomagenesis of mice of the pim-2 18 line, their bi-transgenic progeny also developed prompt pre-B leukemias. The latency was similar to that seen in crosses with the pim-2 30 line (Figure 3) , as was the surface phenotype but immunoglobulin heavy chain gene rearrangement was more advanced and a subclonal light chain rearrangement was observed in one case (arrowed in Figure 5) (Figure 4b ), also indicated a slightly more mature stage of dierentiation than the tumors obtained in crosses with the higher expressing pim-2 30 line. A dierence in the severity of the leukemias was noticeable; peripheral white blood cell counts were lower and mitotic Figures were largely absent from the peripheral blood. As the average ages of the mice sacri®ce were nearly the same as for the pim-2 30/Emmyc mice, the dierence in tumor severity may be attributed to the lower level of pim-2 transgene expression in line 18.
Silencing by X-inactivation does not prevent oncogene collaboration
As noted above, one of the two transgenes should be silenced by X-chromosome inactivation in each cell of the ®rst generation (F1) females of the pim-2 18/Emmyc cross, preventing collaboration. Nevertheless, tumors arose in this cohort much faster than expected (dotted curve in Figure 4 ), albeit more slowly than the prompt pre-B cell leukemias in the second generation bi-transgenics. Most of the tumors in the pim-2 18/Emmyc F1s in fact expressed both transgenes (Figure 7a ). The tumors were clonal with respect to immunoglobulin gene rearrangements (Figure 7b ), so the silencing of one transgene by X-inactivation must have been overcome by some mechanism.
There would clearly be strong selection for such an outcome, acting either on rare cells expressing both transgenes from an early stage of B ontogeny or on stochastic events activating expression of the second transgene at any stage of B-cell development. Several arguments support the latter interpretation. First, the tumors were lymphomas of heterogeneous surface phenotype ranging from CD43 + to IgM + : none were early pre-B cell leukemias. Second, not all the F1 bitransgenic animals succumbed to tumors (Figure 3) . Third, the pim-2 18 transgene was mostly expressed at abnormally high levels in these tumors ± compare the tumors from one F1 female and her bi-transgenic pup, marked`m' and`p' in Figure 8a . Tumors in the F1 animals with the longest latencies, marked`*' and`#' in Figures 3 and 8a , showed low or no expression of the pim-2 18 transgene. The absence of similar dierences in expression of the Em-myc transgene indicates that it was the silencing of the pim-2 18 transgene that was aected and a de®nite order can thus be assigned to the oncogenic events in the etiology of the tumors: constitutive c-myc expression followed by activation of pim-2.
Discussion
The existence of two homologous but distinct pim genes indicates similar but non-identical functions, a premise reinforced by the dierences in basal expression of the two genes in mouse tissues, brain and testis a being notable examples. Messenger RNAs of both pim-1 and pim-2 are, however, expressed at similar levels in the lymphoid organs and bone marrow and, at much higher levels, in lymphoid or myeloid cells stimulated with cytokines or other mitogens. Overlap in their respective functions in these cell types can thus be expected. That this is so in the context of lymphomagenesis was implied by their mutually exclusive activation in MuLV-induced lymphomas Scheijen et al., 1997) + ± not shown) probably derived either from residual or displaced hematopoiesis that a pim-2 transgene should promote lymphomagenesis in a manner similar to a pim-1 transgene and indeed we found no obvious dierences between them in this respect.
The pro/pre-B leukemias observed in the pim-26Em-myc crosses were likewise similar to those obtained previously with pim-16Em-myc crosses (Verbeek et al., 1991) . It is striking that despite an insigni®cant rate of lymphomagenesis in the lower-expressing pim-2 line 18, potent collaboration with the Em-myc transgene still occurred. Remarkably, the synergism between transgenes in these crosses was observed even when Xinactivation should have silenced one of the two transgenes in each cell. It is unlikely that the tumors could have been composed of two populations of cells, each expressing one transgene and supporting each other's growth in a paracrine fashion, as they appeared clonal for immunoglobulin gene rearrangements. The high level of expression of both pim-2 and myc transgenes (compared to tumors carrying only one of them) argues against the possibility that one such population was a very minor constituent, not easily observed by Southern analysis. Rather, the silenced pim-2 transgene was apparently activated at low frequency in cells expressing the Em-myc transgene, leading to clonal tumor outgrowth (see Results). The opportunity for such a`second event' is no doubt increased by the marked expansion of pre-B cells expressing the Em-myc transgene (Langdon et al., 1986) .
We can envisage several mechanisms by which Xinactivation might be circumvented. Leaky expression from the Barr body would clearly be selected for. Mitotic recombination could place both transgenes on the active X-chromosome (the two transgene loci cannot be closely linked, as evidenced by the frequency of meiotic recombination in the second generation of the pim-2 18/Em-myc cross), although that would not explain the unusually high expression of the pim-2 18 transgene. Alternatively, translocations involving the Barr body might activate the silenced transgene. Collaboration between two X-linked transgenes to produce tumors may provide a handle on the frequency of such processes, and the factors which in¯uence them. We know of no other examples where oncogenes on inactive X chromosomes have been implicated in tumorigenesis.
While the pre-B cell tumors in the bi-transgenics were well advanced at birth, it is not yet clear whether activation of the two genes is sucient to generate a full-blown tumor in the B-lineage without further oncogenic events. If so, the tumors should be highly polyclonal and kill the mice early in development. The Ig heavy chain rearrangements observed are ambiguous in this regard ± they appear polyclonal but it is possible that rearrangement occurs independently in subclones of a clonal pro-B tumor (it may be noted that in the cases where simultaneous T-lymphomas were observed, these were clonal). Some of the tumors could be successfully transplanted and all could be grown in vitro, so it may be said with con®dence that the combination of pim-2 and c-myc over-expression leads at the very least to a profound lympho-proliferative syndrome which progresses rapidly to invasive, transplantable tumors. It will thus be interesting to see whether over-expression of the PIM-1 or PIM-2 genes is correlated with the blast crises of any human B-cell malignancies. Thymic T-cell lymphomas were also sometimes present in the bi-transgenic mice. In the cases it was possible to check, these tumors had clonal T-cell receptor rearrangements and were largely con®ned to the thymus, while oligoclonal pre-B cell leukemia dominated in the other lymphoid organs and in circulation. They are thus unlikely to have had a common origin. It appears that independent tumorigenesis in the T-cell compartment is somewhat slower, only sometimes occurring quickly enough to be manifested before the animals succumb to pre-B leukemia. The appearance of B and T cell tumors in the same mouse has been observed previously in bi-transgenic progeny of crosses between the Em-myc and a pim-1 transgenic line, where the latency of tumorigenesis was comparable to the present case (J Allen, unpublished data).
We have stressed the similarities between the oncogenic behaviour of the pim-2 and pim-1 genes, particularly in collaboration with c-myc. It is thus pertinent that the two genes have recently been shown to share another pair of collaborators ± g®-1 and bmi-1 (Scheijen et al., 1997) ± which together form the other major complementation group of proto-oncogenes that synergise with pim and/or myc activations in murine lymphoma models .
Materials and methods
Transgenic mice
The pim-2 gene was obtained by screening a 129SVJ-strain mouse library (Strategene) with a cDNA probe . The 0.95 kb and 3.5 kb EcoRI fragments spanning the coding sequence were joined, omitting the small intervening portion of intron 2 (Figure 2a) . The resulting fragment was inserted at the XhoI site of the vector. The construct thus lacks most of the 3' UTR and the mRNA instability motifs therein. NotI sites¯anking the vector allowed removal of plasmid sequences prior to microinjection into zygotes of FVB mice, by standard procedures (Hogan et al., 1994) .
The Em-myc transgenics contain the Em-SV40 construct used by Adams et al. (1985) . Line 186, on a C57Bl/6 background, is a high transgene copy number line described previously (Verbeek et al., 1991) . Mice used in the present study had been back-crossed to the FVB strain for 10 generations. They exhibit essentially the same pre-neoplastic and tumor phenotype as originally described (Langdon et al., 1986; Harris et al., 1988) .
DNA and RNA analysis
Pim-2 transgenic vs non-transgenic genotypes were distinguished initially by Southern analysis of tail DNAs (to detect a transgene-speci®c 3.2 kb KpnI fragment) and thereafter by PCR with vector-speci®c primers TDK5' CGG CCT TTG ATG GCT TTG and EMU3' AGG GTA TGA GAG AGC CTC, yielding a diagnostic product of 300 bp. Emmyc mice were also identi®ed by PCR; primers matching plasmid sequences in the transgene (CAG CTG GCG TAA -TAG CGA AGA G and CTG TGA CTG GTG AGT ACT -CAA CC ± courtesy of A Harris) yield an 800 bp product.
Pim-2 was detected on Southern and Northern blots using a full-length cDNA probe, and c-myc with an ORF probe. The pim-2 and Em-myc transgene RNAs could be detected speci®cally with U3 LTR and fX174 (Adams et al., 1985) probes respectively. Rearrangements of the TCRb chain were detected with a Jb2 probe (Snodgrass et al., 1985) on HindIIIdigested tumor DNA. Immunoglobulin k light chain and m heavy chain rearrangements were detected with Ck (Lewis et al., 1982) and JH 3/4 (Marcu et al., 1980) probes on DNAs digested with BamHI or EcoRI respectively.
Histology and¯ow cytometry
Tissue specimens were ®xed in acid ethanol/formalin (Harrison, 1984) and sections stained with hematoxylin and eosin. Peripheral blood and tumor cell smears were ®xed in methanol and stained with May-Grunwald-Giemsa or modi®ed Wright's stains. Cell surface markers were stained with¯uorochrome-conjugated monoclonal antibodies and analysed by¯ow cytometry, as described . Cell counts were determined using a Sysmex F-800 Microcell Counter.
Cytokine stimulations, tumor cell cultures and transplantation
Mast cells were grown from femoral plugs as described (Domen et al., 1993a) . T-cell blasts were generated by culturing spleen cells in RPMI-1640, 10% FCS, 10 mM 2-mercaptoethanol (2-ME) and 2 mg/ml concanavalin A for 2 days. Cells were washed three times and re-plated without factor (but with 5% serum) for 2 h at low density (10 5 cells per ml). The washing and starvation steps were repeated before stimulation with saturating levels of cytokines for 2 h. Harvested cells were cooled and frozen promptly, as the pim-2 mRNA is labile.
Pim-2 30/Em-myc bi-transgenic tumor single cell suspensions were obtained from a mixture of spleen, liver and peripheral blood. The cells were cultured as dilution series in RPMI-1640, 10% FCS and 50 mM 2-ME, supplemented with IL-7 and/or SCF. Continuous lines could not be derived without factor. Tumor cell suspensions were washed and transplanted to pairs of young adult FVB females by intraperitoneal injection of 10 
